Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells

• Published in: Cancer research (Chicago, Ill.) Vol. 74; no. 23; pp. 7115 - 7124
• Main Authors: Park, Ilwoo, Mukherjee, Joydeep, Ito, Motokazu, Chaumeil, Myriam M, Jalbert, Llewellyn E, Gaensler, Karin, Ronen, Sabrina M, Nelson, Sarah J, Pieper, Russell O
• Format: Journal Article
• Language: English
• Published: United States 01.12.2014
• Subjects: Apoptosis - drug effects; Apoptosis - genetics; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Carrier Proteins - genetics; Carrier Proteins - metabolism; Cell Line, Tumor; Checkpoint Kinase 1; Dacarbazine - analogs & derivatives; Dacarbazine - pharmacology; DNA Damage - physiology; DNA Repair; Gene Expression - drug effects; Glioblastoma - drug therapy; Glioblastoma - genetics; Glioblastoma - metabolism; Humans; L-Lactate Dehydrogenase - genetics; L-Lactate Dehydrogenase - metabolism; Magnetic Resonance Imaging - methods; Membrane Proteins - genetics; Membrane Proteins - metabolism; Methyltransferases - genetics; Methyltransferases - metabolism; NAD - genetics; NAD - metabolism; Protein Kinases - genetics; Protein Kinases - metabolism; Pyruvic Acid - metabolism; Temozolomide; Thyroid Hormone-Binding Proteins; Thyroid Hormones - genetics; Thyroid Hormones - metabolism
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.can-14-0849

Recent findings show that exposure to temozolomide (TMZ), a DNA-damaging drug used to treat glioblastoma (GBM), can suppress the conversion of pyruvate to lactate. To understand the mechanistic basis for this effect and its potential utility as a TMZ response biomarker, we compared the response of isogenic GBM cell populations differing only in expression of the DNA repair protein methyltransferase (MGMT), a TMZ-sensitivity determinant, after exposure to TMZ in vitro and in vivo. Hyperpolarized [1-((13))C]-pyruvate-based MRI was used to monitor temporal effects on pyruvate metabolism in parallel with DNA-damage responses and tumor cell growth. TMZ exposure decreased conversion of pyruvate to lactate only in MGMT-deficient cells. This effect coincided temporally with TMZ-induced increases in levels of the DNA-damage response protein pChk1. Changes in pyruvate to lactate conversion triggered by TMZ preceded tumor growth suppression and were not associated with changes in levels of NADH or lactate dehydrogenase activity in tumors. Instead, they were associated with a TMZ-induced decrease in the expression and activity of pyruvate kinase PKM2, a glycolytic enzyme that indirectly controls pyruvate metabolism. PKM2 silencing decreased PK activity, intracellular lactate levels, and conversion of pyruvate to lactate in the same manner as TMZ, and Chk1 silencing blocked the TMZ-induced decrease in PKM2 expression. Overall, our findings showed how TMZ-induced DNA damage is linked through PKM2 to changes in pyruvate metabolism, and how these changes can be exploited by MRI methods as an early sensor of TMZ therapeutic response.